SG171601A1 - Further medical uses of antisecretory protein - Google Patents

Further medical uses of antisecretory protein

Info

Publication number
SG171601A1
SG171601A1 SG201102875-0A SG2011028750A SG171601A1 SG 171601 A1 SG171601 A1 SG 171601A1 SG 2011028750 A SG2011028750 A SG 2011028750A SG 171601 A1 SG171601 A1 SG 171601A1
Authority
SG
Singapore
Prior art keywords
caveolae
dysfunction
lipid rafts
antisecretory protein
receptors
Prior art date
Application number
SG201102875-0A
Other languages
English (en)
Inventor
Hans-Arne Hansson
Stefan Lange
Original Assignee
Lantmaennen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmaennen As Faktor Ab filed Critical Lantmaennen As Faktor Ab
Publication of SG171601A1 publication Critical patent/SG171601A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
SG201102875-0A 2006-04-27 2007-04-27 Further medical uses of antisecretory protein SG171601A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0600933 2006-04-27
US92082607P 2007-03-30 2007-03-30

Publications (1)

Publication Number Publication Date
SG171601A1 true SG171601A1 (en) 2011-06-29

Family

ID=38655929

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102875-0A SG171601A1 (en) 2006-04-27 2007-04-27 Further medical uses of antisecretory protein

Country Status (20)

Country Link
US (2) US8309513B2 (de)
EP (2) EP2040734B1 (de)
JP (2) JP5323682B2 (de)
KR (3) KR20090045148A (de)
CN (3) CN104689299B (de)
AT (1) ATE526031T1 (de)
AU (1) AU2007244003B2 (de)
BR (2) BRPI0710794A2 (de)
CA (1) CA2650589C (de)
DK (3) DK2037950T3 (de)
ES (3) ES2615515T3 (de)
HK (1) HK1131738A1 (de)
IL (1) IL194774A (de)
MX (1) MX2008013774A (de)
NZ (2) NZ572256A (de)
PL (2) PL2040734T3 (de)
RU (2) RU2465914C2 (de)
SG (1) SG171601A1 (de)
WO (1) WO2007126363A2 (de)
ZA (2) ZA200809116B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2015767B1 (de) 2006-04-27 2016-01-06 Lantmännen AS-Faktor AB Verwendung des antisekretorischen faktors zur behandlung von erhöhtem augeninnendruck
EP2040734B1 (de) 2006-04-27 2011-09-28 Lantmännen AS-Faktor AB Antisekretorisches protein zur verwendung bei der behandung von kompartiment-syndrom
PL2037950T3 (pl) * 2006-04-27 2014-09-30 Lantmaennen As Faktor Ab Dodatkowe zastosowania medyczne białka antysekrecyjnego
WO2010093324A1 (en) * 2009-02-11 2010-08-19 Lantmännen As-Faktor Ab Use of antisecretory factors (af) for optimizing cellular uptake
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
WO2010065342A1 (en) 2008-11-25 2010-06-10 Temple University Angiocidin inhibition of tumor cell growth
US11253552B2 (en) * 2015-07-10 2022-02-22 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of AF-16
EP3484909B1 (de) * 2016-07-18 2021-06-16 Lantmännen Medical AB Antisekretorischer faktor 17
JP7217760B2 (ja) * 2018-06-28 2023-02-03 ラントメネン・メディカル・アーベー 急性呼吸不全の治療および／または予防の使用のための抗分泌因子
EP3855934A2 (de) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB Verzehrbares produkt mit gemälztem entspelztem hafer
WO2020065091A1 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted wheat
CN115605214A (zh) 2020-03-26 2023-01-13 兰特门内保健食品公司（Se） 用于促进身体活动恢复的包含麦芽化谷物的可消耗产品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) * 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE506486C2 (sv) * 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
US7662169B2 (en) * 2000-09-05 2010-02-16 Wittmann Dietmar H Prosthesis and method for lowering abdominal pressure
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
EP2040734B1 (de) 2006-04-27 2011-09-28 Lantmännen AS-Faktor AB Antisekretorisches protein zur verwendung bei der behandung von kompartiment-syndrom
PL2037950T3 (pl) 2006-04-27 2014-09-30 Lantmaennen As Faktor Ab Dodatkowe zastosowania medyczne białka antysekrecyjnego
WO2009052478A1 (en) * 2007-10-19 2009-04-23 Trustees Of Boston University Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide

Also Published As

Publication number Publication date
ATE526031T1 (de) 2011-10-15
BRPI0710858A2 (pt) 2011-05-17
PL2040734T3 (pl) 2012-04-30
AU2007244003B2 (en) 2012-08-02
ES2472737T3 (es) 2014-07-02
CN101437533A (zh) 2009-05-20
JP5323682B2 (ja) 2013-10-23
JP2011032284A (ja) 2011-02-17
CN101460187A (zh) 2009-06-17
DK2037950T3 (da) 2014-06-30
RU2008146734A (ru) 2010-06-10
ES2374712T3 (es) 2012-02-21
DK2040734T3 (da) 2012-01-23
NZ572257A (en) 2011-10-28
EP2040734B1 (de) 2011-09-28
KR20140123601A (ko) 2014-10-22
CN101437533B (zh) 2016-10-12
KR101757523B1 (ko) 2017-07-12
RU2465914C2 (ru) 2012-11-10
IL194774A0 (en) 2011-08-01
WO2007126363A3 (en) 2008-03-13
CA2650589C (en) 2017-06-13
RU2008146731A (ru) 2010-06-10
JP2009535328A (ja) 2009-10-01
CA2650589A1 (en) 2007-11-08
CN104689299B (zh) 2020-02-21
BRPI0710794A2 (pt) 2011-06-21
EP2363140B1 (de) 2016-12-14
PL2363140T3 (pl) 2017-05-31
MX2008013774A (es) 2009-02-03
NZ572256A (en) 2012-02-24
EP2363140A1 (de) 2011-09-07
WO2007126363A2 (en) 2007-11-08
ZA200809114B (en) 2009-06-24
DK2363140T3 (en) 2017-03-06
US20090185982A1 (en) 2009-07-23
US8389468B2 (en) 2013-03-05
HK1131738A1 (en) 2010-02-05
WO2007126363A8 (en) 2008-10-30
KR101805973B1 (ko) 2017-12-06
JP5285043B2 (ja) 2013-09-11
IL194774A (en) 2015-07-30
US20110305773A1 (en) 2011-12-15
CN104689299A (zh) 2015-06-10
KR20140141729A (ko) 2014-12-10
US8309513B2 (en) 2012-11-13
ES2615515T3 (es) 2017-06-07
RU2457853C2 (ru) 2012-08-10
ZA200809116B (en) 2009-07-29
KR20090045148A (ko) 2009-05-07
AU2007244003A1 (en) 2007-11-08
EP2040734A2 (de) 2009-04-01
CN101460187B (zh) 2014-11-05

Similar Documents

Publication Publication Date Title
SG171601A1 (en) Further medical uses of antisecretory protein
MX2008013777A (es) Usos medicos adicionales de la proteina antisecretora.
WO2010126626A3 (en) Dual mechanism inhibitors for the treatment of disease
WO2008042688A3 (en) Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2011041462A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011041729A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2008080082A3 (en) Methods for modulating set and uses thereof
WO2010141768A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2010077882A3 (en) Antagonists of lysophosphatidic acid receptors
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008054208A3 (en) Use of nutritional compositions for preventing disorders
WO2007120284A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
HK1127289A1 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl- propyl) -phenol and paracetamol
WO2009038385A3 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same